Page 1

TWIST BIOSCIENCE Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results February 4 , 2021 SOUTH SAN FRANCISCO , Calif .-- ( BUSINESS WIRE ) -- Feb . 4 , 2021-- Twist Bioscience Corporation ( NASDAQ : TWST ) , a company enabling customers to succeed through its offering of high - quality synthetic DNA using its silicon platform , today reported financial results and business highlights for the first quarter of fiscal 2021 ended December 31 , 2020 . " We reported a strong quarter both for orders and revenue , building a solid foundation for fiscal 2021 , " said Emily M. Leproust , Ph.D. , CEO and co - founder of Twist Bioscience . " We see early evidence that our investment in synbio products for our pharmaceutical and biotech customers is beginning to gain traction , and for our NGS tools business , our liquid biopsy customers continue to drive revenue growth . Both our biopharma and DNA data storage teams made progress in advancing technologies , and we strengthened our balance sheet with $ 324 million through a recent equity offering . " Looking ahead , we expect continued growth and diversification of our revenue stream as we build out our Factory of the Future as a second site in Oregon , continued focus on offering a business - to - business solution for multi - site institutions and a full launch of our NGS methylation solution . In addition , we anticipate out - licensing our first internally - generated antibodies and continued progress for our DNA data storage business . " FISCAL 2021 FIRST QUARTER FINANCIAL RESULTS • Orders : Total orders received for the first quarter of fiscal 2021 were $ 33.6 million , compared to $ 24.8 million for the same period of fiscal 2020 . • Revenue : Total revenues were $ 28.2 million for the first quarter of fiscal 2021 compared to $ 17.2 million for the same period of fiscal 2020 . • Cost of Revenues : Cost of revenues for the first quarter of fiscal 2021 was $ 18.2 million compared to $ 13.8 million for the same period of fiscal 2020 . • Research and Development Expenses : Research and development expenses for the first quarter of fiscal 2021 were $ 14.0 million compared to $ 10.3 million for the same period of fiscal 2020 . • Selling , General and Administrative Expenses : Selling , general and administrative expenses for the first quarter of fiscal 2021 were $ 28.8 million compared to $ 26.4 million for the same period of fiscal 2020 . • Net Loss : Net loss for the first quarter of fiscal 2021 was $ 32.9 million , or $ 0.72 per share , compared to $ 55.6 million , or $ 1.69 per share , for the first quarter of fiscal 2020 . • Cash Position : As of December 31 , 2020 , the company had $ 587.3 million in cash , cash equivalents and short - term investments . " We delivered another very strong quarter in what continues to be an uncertain environment due to the global pandemic , " commented Jim Thorburn , CFO of Twist . " We remain well positioned to leverage our DNA synthesis platform into growing market opportunities today as we plan for future success in the years ahead . " Fiscal First Quarter 2021 and Recent Highlights ● Shipped products to approximately 1,500 customers in the first quarter of fiscal 2021 versus approximately 1,000 in the same period of fiscal 2020 . • Launched Clonal - Ready Gene Fragments , providing customers with a complete offering for genes . Twist's best - in - class Gene Fragments , with and without adapters , can be used to build constructs and minimize the time and cost of screening for perfect clones . The resulting product is a ready - to - use Gene Fragment that is compatible with many applications including cloning , gene and protein expression , pathway and enzyme engineering and enzyme optimization . • Announced plans to expand its manufacturing and commercial capabilities with the addition of the " Factory of the Future " just outside of Portland , Oregon in Wilsonville . The 110,000 - square - foot facility is expected to become operational in 2022 . • Introduced new synthetic RNA controls to develop , validate and verify tests for SARS - CoV - 2 . The new controls include the B.1.1.7 variant of SARS - CoV - 2 . • Supplied the U.S. Centers for Disease Control and Prevention ( CDC ) with a customized version of Twist SARS - CoV - 2 Synthetic RNA Controls for use in the CDC Influenza SARS - CoV - 2 ( Flu SC2 ) Multiplex Assay , an assay that tests for influenza A , B and SARS - CoV - 2 simultaneously . In addition to using the assay at its primary site , CDC intends to distribute this multiplex assay to additional public health laboratories for testing across the United States . • Signed two licensing agreements with Serotiny and Applied StemCell . In collaboration with Serotiny , Twist Biopharma aims to discover novel Chimeric Antigen Receptors ( CAR ) for CAR T - Cell therapies . The agreement with Applied StemCell ,